Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 9/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 5/20 | 0.43 |
| ▸ | CDC25A | P30304 | 1/20 | 0.43 |
| ▸ | ICMT | O60725 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11623169 | 0.88 | MEN1 (0.51) | MEN1KMT2ACNR2HDAC1HDAC2 | |
| SCHEMBL7712112 | 0.85 | CNR2 (0.59) | CNR2CNR1CDC25AICMT | |
| SCHEMBL8363931 | 0.83 | CDC25A (0.59) | CNR2CNR1CDC25AICMT | |
| SCHEMBL14947367 | 0.83 | CDC25A (0.59) | CNR2CNR1CDC25AICMT | |
| SCHEMBL12206640 | 0.83 | CNR2 (0.54) | MEN1KMT2ACNR2CNR1CDC25A | |
| SCHEMBL3078397 | 0.81 | CDC25A (0.57) | CNR2CNR1CDC25AICMT | |
| SCHEMBL20221429 | 0.79 | MEN1 (0.53) | MEN1KMT2ACNR2HDAC1HDAC2 | |
| SCHEMBL8612793 | 0.79 | CNR2 (0.56) | MEN1KMT2ACNR2CNR1 | |
| SCHEMBL90184 | 0.79 | CNR2 (0.56) | MEN1KMT2ACNR2HDAC1HDAC2 | |
| SCHEMBL20054193 | 0.77 | MEN1 (0.51) | MEN1KMT2ACNR2HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | MEN1 2817/4885KMT2A 3839/4885CNR2 1456/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | MEN1 2817/4885KMT2A 3839/4885CNR2 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.